Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716754 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 471
- Enrollment target
NCT01716754 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 471 participants.
The verdict
NCT01716754, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 471 participants
- Enrollment target
Study Summary
This study assessed the effect on asthma control of different dose levels and regimens of QGE031 in asthma patients that are inadequately controlled with inhaled steroid and beta-2 agonist medication. Safety was assessed also. Comparison was to placebo and omalizumab. Information from this study was planned to support the design of future studies.
Interventions
- DRUG Placebo
- DRUG Omalizumab
- DRUG QGE031
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2012-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01716754
The ClinicalTrials.gov registry entry for NCT01716754 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 471 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01716754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01716754 about?
NCT01716754 is a clinical study titled "Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma". This study assessed the effect on asthma control of different dose levels and regimens of QGE031 in asthma patients that are inadequately controlled with inhaled steroid and beta-2 agonist medication. Safety was assessed also. Comparison was to placebo and omalizumab. Information from this study was...
What is the current status of trial NCT01716754?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 471 participants. The study started on 2012-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01716754?
The interventions under investigation include: Placebo (DRUG), Omalizumab (DRUG), QGE031 (DRUG).
Who is sponsoring clinical trial NCT01716754?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.